Cargando…
Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series
Clinical studies have shown that bismuth-containing quadruple therapy given twice a day for 10 to 14 days is effective and safe in the treatment of Helicobacter pylori infection in Sardinia. However, bismuth is no longer available in Italy. To report the effectiveness and tolerability of pantoprazol...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839865/ https://www.ncbi.nlm.nih.gov/pubmed/27082621 http://dx.doi.org/10.1097/MD.0000000000003411 |
_version_ | 1782428204734087168 |
---|---|
author | Dore, Maria P. Soro, Sara Rocchi, Chiara Loria, Maria F. Bibbò, Stefano Pes, Giovanni M. |
author_facet | Dore, Maria P. Soro, Sara Rocchi, Chiara Loria, Maria F. Bibbò, Stefano Pes, Giovanni M. |
author_sort | Dore, Maria P. |
collection | PubMed |
description | Clinical studies have shown that bismuth-containing quadruple therapy given twice a day for 10 to 14 days is effective and safe in the treatment of Helicobacter pylori infection in Sardinia. However, bismuth is no longer available in Italy. To report the effectiveness and tolerability of pantoprazole 20 mg, tetracycline 500 mg, and metronidazole 500 mg given b.i.d. (with the midday and evening meals) for 10 days supplemented with Lactobacillus reuteri (DSM 17938) 10(8) cfu/tablet once a day for 20 days in patients treated in a routine daily practice setting. H pylori infection was defined as a positive gastric histopathology and/or (13)C-Urea Breath Test (UBT) and/or stool antigen testing. Successful eradication was documented by (13)C-UBT, and/or stool antigen assay at least 4 weeks post-therapy. Compliance and side effects were recorded after completing treatment. A total of 45 patients (10 men, 35 women; mean age 52.6 years) have completed the treatment regimen with the success rate of 93% (95% confidence interval = 85–99%). Compliance was excellent. Side effects were absent or generally mild. Proton pump inhibitor-tetracycline-metronidazole-L reuteri therapy provided high eradication rates with few side effects and therefore can safely replace bismuth in H pylori treatment. Further studies are needed that include susceptibility testing. |
format | Online Article Text |
id | pubmed-4839865 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-48398652016-06-02 Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series Dore, Maria P. Soro, Sara Rocchi, Chiara Loria, Maria F. Bibbò, Stefano Pes, Giovanni M. Medicine (Baltimore) 4900 Clinical studies have shown that bismuth-containing quadruple therapy given twice a day for 10 to 14 days is effective and safe in the treatment of Helicobacter pylori infection in Sardinia. However, bismuth is no longer available in Italy. To report the effectiveness and tolerability of pantoprazole 20 mg, tetracycline 500 mg, and metronidazole 500 mg given b.i.d. (with the midday and evening meals) for 10 days supplemented with Lactobacillus reuteri (DSM 17938) 10(8) cfu/tablet once a day for 20 days in patients treated in a routine daily practice setting. H pylori infection was defined as a positive gastric histopathology and/or (13)C-Urea Breath Test (UBT) and/or stool antigen testing. Successful eradication was documented by (13)C-UBT, and/or stool antigen assay at least 4 weeks post-therapy. Compliance and side effects were recorded after completing treatment. A total of 45 patients (10 men, 35 women; mean age 52.6 years) have completed the treatment regimen with the success rate of 93% (95% confidence interval = 85–99%). Compliance was excellent. Side effects were absent or generally mild. Proton pump inhibitor-tetracycline-metronidazole-L reuteri therapy provided high eradication rates with few side effects and therefore can safely replace bismuth in H pylori treatment. Further studies are needed that include susceptibility testing. Wolters Kluwer Health 2016-04-18 /pmc/articles/PMC4839865/ /pubmed/27082621 http://dx.doi.org/10.1097/MD.0000000000003411 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0, where it is permissible to download, share and reproduce the work in any medium, provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | 4900 Dore, Maria P. Soro, Sara Rocchi, Chiara Loria, Maria F. Bibbò, Stefano Pes, Giovanni M. Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series |
title | Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series |
title_full | Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series |
title_fullStr | Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series |
title_full_unstemmed | Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series |
title_short | Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series |
title_sort | inclusion of lactobacillus reuteri in the treatment of helicobacter pylori in sardinian patients: a case report series |
topic | 4900 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839865/ https://www.ncbi.nlm.nih.gov/pubmed/27082621 http://dx.doi.org/10.1097/MD.0000000000003411 |
work_keys_str_mv | AT doremariap inclusionoflactobacillusreuteriinthetreatmentofhelicobacterpyloriinsardinianpatientsacasereportseries AT sorosara inclusionoflactobacillusreuteriinthetreatmentofhelicobacterpyloriinsardinianpatientsacasereportseries AT rocchichiara inclusionoflactobacillusreuteriinthetreatmentofhelicobacterpyloriinsardinianpatientsacasereportseries AT loriamariaf inclusionoflactobacillusreuteriinthetreatmentofhelicobacterpyloriinsardinianpatientsacasereportseries AT bibbostefano inclusionoflactobacillusreuteriinthetreatmentofhelicobacterpyloriinsardinianpatientsacasereportseries AT pesgiovannim inclusionoflactobacillusreuteriinthetreatmentofhelicobacterpyloriinsardinianpatientsacasereportseries |